AlphAIAlphAI — Financial news for AI agents
investing.comOCT 292 min read$MDGL

B.Riley reiterates Buy on Madrigal stock, $670 target on sales

B.Riley reiterated a Buy rating and $670 price target on Madrigal Pharmaceuticals (MDGL) ahead of Q3 earnings, citing U.S. Rezdiffra sales expected above consensus. Analysts highlight strong sales growth and potential upside. MDGL shares are down 26% YTD but trade below Fair Value. The company's market cap is $9.96B, and it maintains a 91% gross profit margin. Multiple analysts have recently adjusted their ratings and targets for MDGL.

Original reporting
investing.com
Published Oct 29, 2026, 9:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MDGL
Bullish
medium confidence
Mentioned
$MDGL
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MDGLBullishMed
01

Why it matters

Analyst upgrades and higher targets could drive short‑term buying interest ahead of earnings, but the stock's volatility and recent price decline pose risk.

02

Market read

Analyst consensus upgrades may create a modest bullish catalyst for MDGL before its earnings release.

03

What to watch

Potential regulatory or trial setbacks for Rezdiffra could temper upside.

Relevance 6/10Novelty 6/10Timing: pre‑earnings today

Background

Madrigal Pharmaceuticals (MDGL) is a biotech company developing Rezdiffra for NASH, with upcoming Q3 earnings and ongoing Phase 3 trial.

Company-level read

Ticker impact

$MDGLBullishMedium confidence
Context

B.Riley and several analysts reiterated Buy ratings and raised price targets for Madrigal Pharmaceuticals ahead of its Q3 earnings, providing fresh valuation guidance.

Expected impact

likely upward pressure as traders price in higher targets

Evidence & confidence

Multiple buy ratings and higher price targets indicate renewed confidence, which can attract buying before earnings.

Market effects

Sector

Positive sentiment may lift other biotech stocks focused on niche therapies.

Regional

Limited to US biotech sector.

Global

Minor, confined to investors tracking specialty pharma.

Counterpoint

What could challenge this read

The stock remains down 26% YTD; price targets may be overly optimistic without new data.

Key entities

  • Analyst
    B.Riley

    Reiterated Buy rating and $670 price target.

  • Analyst
    UBS

    Raised price target to $735.

Read at source← All news

Related articles

OCT 14
$MDGLMed

UBS raises Madrigal Pharmaceuticals stock price target on F4 trial outlook

UBS raised its price target for Madrigal Pharmaceuticals (MDGL) to $735 from $669, citing a higher probability of success for its F4 program. The stock is currently trading at $452.12, down 22% year-to-date, but analysts maintain a Strong Buy consensus. The company reported Q2 2026 net sales of $364.3 million for Rezdiffra, up 71% year-over-year, but faced a wider net loss and rising expenses. Multiple analysts have adjusted their price targets and ratings for MDGL.

investing.com2 min
OCT 6
$MDGLMedAI 8/10

Madrigal’s Rezdiffra shows consistent results across genetic variants in MASH trial

Madrigal Pharmaceuticals (MDGL) published a secondary analysis from its Phase 3 MAESTRO-NASH trial, showing Rezdiffra's effectiveness across genetic variants in MASH patients. The study found consistent fibrosis improvement and MASH resolution in treated groups. The company plans to consult with the FDA on a Phase 2 combination trial with Rezdiffra and MGL-0795. Rezdiffra is approved for MASH treatment and is being tested for cirrhosis.

investing.com2 min
JUL 30
$MDGLMed

Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates • Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% • As of June 30, 2026, more than 49,000 patient

SEC EDGAR 8-K6 min
OCT 29
$GNSSMed

Genasys Inc. Announces Preliminary Unaudited Fiscal Fourth Quarter and Full Fiscal Year 2026 Financial Results

Genasys Inc. (GNSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Genasys Inc. Announces Preliminary Unaudited Fiscal Fourth Quarter and Full Fiscal Year 2026 Financial Results Expected Fiscal Year Revenue of $60.5M to $62.0M Expected Fiscal Year Adjusted EBITDA of $7.2M to $8.2M Earnings Call Scheduled for December 15, 2026 SAN DIEGO, CA – Oct

SEC EDGAR 8-K6 min
OCT 29
$NMRKMedAI 8/10

Newmark Reports Third Quarter 2026 Financial Results

NEWMARK GROUP, INC. (NMRK) filed an SEC Form 8-K — Results of Operations and Financial Condition. /////////;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;; 1 Newmark Reports Third Quarter 2026 Financial Results NEW YORK, NY - October 29, 2026 - Newmark Group, Inc. (Nasdaq: NMRK) ("Newmark" or "the Company"), a leading commercial real estate advisor and service provid

SEC EDGAR 8-K2 min